Bishal Gyawali, Editorial Board

Bishal Gyawali: Why Surrogate Endpoints Shouldn’t Justify Full Cancer Drug Approvals

Bishal Gyawali, Associate Professor at Queen’s University, posted on X:

“New video in my Medscape Skills Lab Video Series has just gone live. Perfect timing because this one discusses the role of surrogate endpoints in regulatory approvals- a major theme at ASCO25.
Watch or read to empower yourselves with skills so that you don’t need to outsource critical appraisal to others.”

Watch Further.

Bishal Gyawali: Why Surrogate Endpoints Shouldn’t Justify Full Cancer Drug Approvals

More posts featuring ASCO25.